Aclaris Therapeutics, Inc.
ACRS
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Conā¦ read more
Healthcare
Diagnostics & Research
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.14
Price+1.95%
$0.06
1Y
Price
Market Cap
$340.204m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-436.6%
EBITDA Margin-443.0%
Net Profit Margin-332.1%
Free Cash Flow MarginRevenue
$15.742m
-15.9%
1y CAGR-17.0%
3y CAGR+72.3%
5y CAGREarnings
-$141.680m
-7.3%
1y CAGR-19.4%
3y CAGR-13.5%
5y CAGREPS
-$1.38
+19.3%
1y CAGR-3.6%
3y CAGR+1.5%
5y CAGRBook Value
$120.100m
$175.534m
Assets$55.434m
Liabilities$2.244m
DebtDebt to Assets
1.3%
-
Debt to EBITDAFree Cash Flow
-$78.817m
-290.3%
1y CAGR-77.5%
3y CAGR-65.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company